Can lithium salts prevent depressive episodes in the real world?

European Neuropsychopharmacology

Volumn 28, Issue 12, 2018, Pages 1351-1359

  González Pinto, Ana ^a,b   López Peña, Purificación ^a,b   Bermúdez Ampudia, Cristina ^c   Vieta, Eduard ^d   Martinez Cengotitabengoa, Mónica ^a,b,e  

^a CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE SALUD MENTAL CIBERSAM   (Spain)

^b UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^c Subdirección de enfermería   (Spain)

^d UNIVERSITY OF BARCELONA   (Spain)

^e UNIVERSIDAD NACIONAL DE EDUCACIÓN A DISTANCIA   (Spain)

Author keywords

Compliance; Depression; Lithium

Indexed keywords

LITHIUM CARBONATE; PSYCHOTROPIC AGENT;

ADULT; ALCOHOL ABUSE; ARTICLE; BIPOLAR DISORDER; CLINICAL PRACTICE; DEPRESSION; DRUG ABUSE; DRUG DEPENDENCE; DRUG EFFICACY; FEMALE; HEALTH CARE COST; HOSPITAL ADMISSION; HOSPITALIZATION COST; HUMAN; HYPOMANIA; MAJOR CLINICAL STUDY; MALE; MANIA; MEDICATION COMPLIANCE; MIXED MANIA AND DEPRESSION; PATIENT COMPLIANCE; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; RELAPSE; ECONOMICS; FOLLOW UP; PSYCHOLOGY; RECURRENT DISEASE; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

ADULT; BIPOLAR DISORDER; DEPRESSION; FEMALE; FOLLOW-UP STUDIES; HEALTH CARE COSTS; HUMANS; LITHIUM CARBONATE; MALE; MEDICATION ADHERENCE; PATIENT ADMISSION; PSYCHOTROPIC DRUGS; RECURRENCE; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 85053715702     PISSN: 0924977X     EISSN: 18737862     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2018.09.008     Document Type: Article

References (70)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR), Text Revision. Fourth ed., 2000, American Psychiatric Association, Washington, DC.
2. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-III-R), Text Revision. Third ed., 1987, American Psychiatric Association, Washington, DC.
3. Balanzá-Martínez, V., Crespo-Facorro, B., González-Pinto, A., Vieta, E., Bipolar disorder comorbid with alcohol use disorder: focus on neurocognitive correlates. Front. Physiol., 6, 2015, 108, 10.3389/fphys.2015.00108.
4. Baldessarini, R.J., Lipinski, J.F., Lithium salts: 1970-1975. Ann. Intern. Med. 83 (1975), 527–533.
5. Barbeito, S., Vega, P., Ruiz de Azua, S., Balanza-Martinez, V., Colom, F., Lorente, E., Luengo, A., Cerrillo, E., Crespo, J.M., González Pinto, A., Integrated treatment of first episode psychosis with online training (e-learning): study protocol for a randomised controlled trial. Trials, 15, 2014, 416, 10.1186/1745-6215-15-416.
6. Barbeito, S., Vega, P., Ruiz de Azúa, S., Saenz, M., Martinez-Cengotitabengoa, M., González-Ortega, I., Bermudez, C., Hernanz, M., Corres, B.F., de, González-Pinto, A., Cannabis use and involuntary admission may mediate long-term adherence in first-episode psychosis patients: a prospective longitudinal study. BMC Psychiatry, 13, 2013, 326, 10.1186/1471-244X-13-326.
7. Berk, M., Berk, L., Mood stabilizers and treatment adherence in bipolar disorder: addressing adverse events. Ann. Clin. Psychiatry Off. J. Am. Acad. Clin. Psychiatr. 15 (2003), 217–224.
8. Callaly, E., Walder, K., Morris, G., Maes, M., Debnath, M., Berk, M., Mitochondrial dysfunction in the pathophysiology of bipolar disorder: effects of pharmacotherapy. Mini Rev. Med. Chem. 15 (2015), 355–365.
9. Chen, G., Zeng, W.Z., Yuan, P.X., Huang, L.D., Jiang, Y.M., Zhao, Z.H., Manji, H.K., The mood-stabilizing agents lithium and valproate robustly increase the levels of the neuroprotective protein bcl-2 in the CNS. J. Neurochem. 72 (1999), 879–882.
10. Cipriani, A., Barbui, C., Salanti, G., Rendell, J., Brown, R., Stockton, S., Purgato, M., Spineli, L.M., Goodwin, G.M., Geddes, J.R., Comparative efficacy and acceptability of antimanic drugs in acute mania: a multiple-treatments meta-analysis. Lancet 378 (2011), 1306–1315, 10.1016/S0140-6736(11)60873-8.
11. Clay, H.B., Sillivan, S., Konradi, C., Mitochondrial dysfunction and pathology in bipolar disorder and schizophrenia. Int. J. Dev. Neurosci. 29 (2011), 311–324, 10.1016/j.ijdevneu.2010.08.007 Off. J. Int. Soc. Dev. Neurosci.
12. Curran, G., Ravindran, A., Lithium for bipolar disorder: a review of the recent literature. Expert Rev. Neurother. 14 (2014), 1079–1098, 10.1586/14737175.2014.947965.
13. de Sousa, R.T., Streck, E.L., Zanetti, M.V., Ferreira, G.K., Diniz, B.S., Brunoni, A.R., Busatto, G.F., Gattaz, W.F., Machado-Vieira, R., Lithium increases leukocyte mitochondrial complex I activity in bipolar disorder during depressive episodes. Psychopharmacology (Berl.) 232 (2015), 245–250, 10.1007/s00213-014-3655-6.
14. de Souza, C., Vedana, K.G.G., Mercedes, B.P.doC., Miasso, A.I., Bipolar disorder and medication: adherence, patients’ knowledge and serum monitoring of lithium carbonate. Rev. Lat. Am. Enfermagem 21 (2013), 624–631.
15. Duman, R.S., Neurobiology of stress, depression, and rapid acting antidepressants: remodeling synaptic connections. Depress. Anxiety 31 (2014), 291–296, 10.1002/da.22227.
16. Edwards, S.J., Hamilton, V., Nherera, L., Trevor, N., Lithium or an atypical antipsychotic drug in the management of treatment-resistant depression: a systematic review and economic evaluation. Health Technol. Assess. Winch. Engl. 17 (2013), 1–190, 10.3310/hta17540.
17. First, M.D., Spitzer, R.L., Gibbon, M., Williams, J.B.V., Structured Clinical Interview for DSM-IV Axis I Disorders- Patient Edition (SCID I/P), Version 2.0. Biometrics Research Department. 1995, New York State Psychiatric Institute, New York.
18. García, S., Martínez-Cengotitabengoa, M., López-Zurbano, S., Zorrilla, I., López, P., Vieta, E., González-Pinto, A., Adherence to antipsychotic medication in bipolar disorder and schizophrenic patients: a systematic review. J. Clin. Psychopharmacol. 36 (2016), 355–371, 10.1097/JCP.0000000000000523.
19. Geddes, J.R., Burgess, S., Hawton, K., Jamison, K., Goodwin, G.M., Long-term lithium therapy for bipolar disorder: systematic review and meta-analysis of randomized controlled trials. Am. J. Psychiatry 161 (2004), 217–222, 10.1176/appi.ajp.161.2.217.
20. Geddes, J.R., Miklowitz, D.J., Treatment of bipolar disorder. Lancet Lond. Engl. 381 (2013), 1672–1682, 10.1016/S0140-6736(13)60857-0.
21. Geoffroy, P.A., Bellivier, F., Henry, C., [Treatment of manic phases of bipolar disorder: critical synthesis of international guidelines]. L'Encéphale 40 (2014), 330–337, 10.1016/j.encep.2013.10.007.
22. González-Ortega, I., Ugarte, A., Ruiz de Azúa, S., Núñez, N., Zubia, M., Ponce, S., Casla, P., Llano, J.X., Faria, Á., González-Pinto, A., Online psycho-education to the treatment of bipolar disorder: protocol of a randomized controlled trial. BMC Psychiatry, 16, 2016, 452, 10.1186/s12888-016-1159-0.
23. González-Pinto, Ana, Alberich, S., Barbeito, S., Alonso, M., Vieta, E., Martínez-Arán, A., Saenz, M., López, P., Different profile of substance abuse in relation to predominant polarity in bipolar disorder: the Vitoria long-term follow-up study. J. Affect. Disord. 124 (2010), 250–255, 10.1016/j.jad.2009.11.005.
24. González-Pinto, A., Aldama, A., Mosquera, F., González Gómez, C., Epidemiology, diagnosis and management of mixed mania. CNS Drugs 21 (2007), 611–626.
25. González-Pinto, A., Barbeito, S., Alonso, M., Alberich, S., Haidar, M.K., Vieta, E., Tabarés-Seisdedos, R., Zorrilla, I., González-Pinto, M.A., López, P., Poor long-term prognosis in mixed bipolar patients: 10-year outcomes in the Vitoria prospective naturalistic study in Spain. J. Clin. Psychiatry 72 (2011), 671–676, 10.4088/JCP.09m05483yel.
26. Gonzalez-Pinto, A., Gonzalez, C., Enjuto, S., Fernandez de Corres, B., Lopez, P., Palomo, J., Gutierrez, M., Mosquera, F., Perez de Heredia, J.L., Psychoeducation and cognitive-behavioral therapy in bipolar disorder: an update. Acta Psychiatr. Scand. 109 (2004), 83–90.
27. Gonzalez-Pinto, A., Mosquera, F., Alonso, M., López, P., Ramírez, F., Vieta, E., Baldessarini, R.J., Suicidal risk in bipolar I disorder patients and adherence to long-term lithium treatment. Bipolar Disord. 8 (2006), 618–624, 10.1111/j.1399-5618.2006.00368.x.
28. Gonzalez-Pinto, A.M., Dardennes, R., de Zélicourt, M., López, P., Oliveros, R.G., Vieta, E., Barbeito, S., Echevarria, E., Fagnani, F., In-patient care costs of patients with bipolar I disorder: a comparison between two European centers. J. Affect. Disord. 121 (2010), 152–155, 10.1016/j.jad.2009.05.010.
29. Goodwin, G.M., Haddad, P.M., Ferrier, I.N., Aronson, J.K., Barnes, T., Cipriani, A., Coghill, D.R., Fazel, S., Geddes, J.R., Grunze, H., Holmes, E.A., Howes, O., Hudson, S., Hunt, N., Jones, I., Macmillan, I.C., McAllister-Williams, H., Miklowitz, D.R., Morriss, R., Munafò M., Paton, C., Saharkian, B.J., Saunders, K., Sinclair, J., Taylor, D., Vieta, E., Young, A.H., Evidence-based guidelines for treating bipolar disorder: revised third edition recommendations from the British Association for Psychopharmacology. J. Psychopharmacol. Oxf. Engl., 2016, 10.1177/0269881116636545.
30. Grande, I., Berk, M., Birmaher, B., Vieta, E., Bipolar disorder. Lancet Lond. Engl. 387 (2016), 1561–1572, 10.1016/S0140-6736(15)00241-X.
31. Granek, L., Danan, D., Bersudsky, Y., Osher, Y., Living with bipolar disorder: the impact on patients, spouses, and their marital relationship. Bipolar Disord 18 (2016), 192–199, 10.1111/bdi.12370.
32. Haj-Mirzaian, A., Amiri, S., Kordjazy, N., Momeny, M., Razmi, A., Rahimi-Balaei, M., Amini-Khoei, H., Haj-Mirzaian, A., Marzban, H., Mehr, S.E., Ghaffari, S.H., Dehpour, A.R., Lithium attenuated the depressant and anxiogenic effect of juvenile social stress through mitigating the negative impact of interlukin-1β and nitric oxide on hypothalamic-pituitary-adrenal axis function. Neuroscience 315 (2016), 271–285, 10.1016/j.neuroscience.2015.12.024.
33. Harvey, N.S., The development and descriptive use of the lithium attitudes questionnaire. J. Affect. Disord. 22 (1991), 211–219.
34. Jin, H., McCrone, P., Cost-of-illness studies for bipolar disorder: systematic review of international studies. Pharmacoeconomics 33 (2015), 341–353, 10.1007/s40273-014-0250-y.
35. Jope, R.S., Nemeroff, C.B., Lithium to the rescue. Cerebrum Dana Forum Brain Sci. 2016 (2016), 2–16.
36. Kato, T., Neurobiological basis of bipolar disorder: Mitochondrial dysfunction hypothesis and beyond. Schizophr. Res., 2016, 10.1016/j.schres.2016.10.037.
37. Kato, T., Kato, N., Mitochondrial dysfunction in bipolar disorder. Bipolar Disord. 2 (2000), 180–190.
38. Ketter, T.A., Houston, J.P., Adams, D.H., Risser, R.C., Meyers, A.L., Williamson, D.J., Tohen, M., Differential efficacy of olanzapine and lithium in preventing manic or mixed recurrence in patients with bipolar I disorder based on number of previous manic or mixed episodes. J. Clin. Psychiatry 67 (2006), 95–101.
39. Ketter, T.A., Miller, S., Dell'Osso, B., Wang, P.W., Treatment of bipolar disorder: Review of evidence regarding quetiapine and lithium. J. Affect. Disord. 191 (2016), 256–273, 10.1016/j.jad.2015.11.002.
40. Kleine-Budde, K., Touil, E., Moock, J., Bramesfeld, A., Kawohl, W., Rössler, W., Cost of illness for bipolar disorder: a systematic review of the economic burden. Bipolar Disord. 16 (2014), 337–353, 10.1111/bdi.12165.
41. Krüger, S., Trevor Young, L., Bräunig, P., Pharmacotherapy of bipolar mixed states. Bipolar Disord. 7 (2005), 205–215, 10.1111/j.1399-5618.2005.00197.x.
42. Lähteenvuo, M., Tanskanen, A., Taipale, H., Hoti, F., Vattulainen, P., Vieta, E., Tiihonen, J., Real-world effectiveness of pharmacologic treatments for the prevention of rehospitalization in a Finnish nationwide cohort of patients with bipolar disorder. JAMA Psychiatry., 2018, 10.1001/jamapsychiatry.2017.4711.
43. Martin-Carrasco, M., Gonzalez-Pinto, A., Galan, J.L., Ballesteros, J., Maurino, J., Vieta, E., Number of prior episodes and the presence of depressive symptoms are associated with longer length of stay for patients with acute manic episodes. Ann. Gen. Psychiatry, 11, 2012, 7, 10.1186/1744-859X-11-7.
44. Martinez-Aran, A., Scott, J., Colom, F., Torrent, C., Tabares-Seisdedos, R., Daban, C., Leboyer, M., Henry, C., Goodwin, G.M., Gonzalez-Pinto, A., Cruz, N., Sanchez-Moreno, J., Vieta, E., Treatment nonadherence and neurocognitive impairment in bipolar disorder. J. Clin. Psychiatry 70 (2009), 1017–1023, 10.4088/JCP.08m04408.
45. Maurer, I.C., Schippel, P., Volz, H.-P., Lithium-induced enhancement of mitochondrial oxidative phosphorylation in human brain tissue. Bipolar Disord. 11 (2009), 515–522, 10.1111/j.1399-5618.2009.00729.x.
46. McInerney, S.J., Kennedy, S.H., Review of evidence for use of antidepressants in bipolar depression. Prim. Care Comp. CNS Disord., 16, 2014, 10.4088/PCC.14r01653.
47. Mertens, J., Wang, Q.-W., Kim, Y., Yu, D.X., Pham, S., Yang, B., Zheng, Y., Diffenderfer, K.E., Zhang, J., Soltani, S., Eames, T., Schafer, S.T., Boyer, L., Marchetto, M.C., Nurnberger, J.I., Calabrese, J.R., Ødegaard, K.J., McCarthy, M.J., Zandi, P.P., Alda, M., Alba, M., Nievergelt, C.M. Pharmacogenomics of Bipolar Disorder Study, Mi, S., Brennand, K.J., Kelsoe, J.R., Gage, F.H., Yao, J., Differential responses to lithium in hyperexcitable neurons from patients with bipolar disorder. Nature 527 (2015), 95–99, 10.1038/nature15526.
48. Mora, E., Portella, M.J., Forcada, I., Vieta, E., Mur, M., A preliminary longitudinal study on the cognitive and functional outcome of bipolar excellent lithium responders. Compr. Psychiatry 71 (2016), 25–32, 10.1016/j.comppsych.2016.07.008.
49. Motaghinejad, M., Seyedjavadein, Z., Motevalian, M., Asadi, M., The neuroprotective effect of lithium against high dose methylphenidate: Possible role of BDNF. Neurotoxicology 56 (2016), 40–54, 10.1016/j.neuro.2016.06.010.
50. Murru, A., Pacchiarotti, I., Amann, B.L., Nivoli, A.M.A., Vieta, E., Colom, F., Treatment adherence in bipolar I and schizoaffective disorder, bipolar type. J. Affect. Disord. 151 (2013), 1003–1008, 10.1016/j.jad.2013.08.026.
51. Nierenberg, A.A., McElroy, S.L., Friedman, E.S., Ketter, T.A., Shelton, R.C., Deckersbach, T., McInnis, M.G., Bowden, C.L., Tohen, M., Kocsis, J.H., Calabrese, J.R., Kinrys, G., Bobo, W.V., Singh, V., Kamali, M., Kemp, D., Brody, B., Reilly-Harrington, N.A., Sylvia, L.G., Shesler, L.W., Bernstein, E.E., Schoenfeld, D., Rabideau, D.J., Leon, A.C., Faraone, S., Thase, M.E., Bipolar CHOICE (Clinical Health Outcomes Initiative in Comparative Effectiveness): a pragmatic 6-month trial of lithium versus quetiapine for bipolar disorder. J. Clin. Psychiatry 77 (2016), 90–99, 10.4088/JCP.14m09349.
52. Nolen, W.A., More robust evidence for the efficacy of lithium in the long-term treatment of bipolar disorder: should lithium (again) be recommended as the single preferred first-line treatment?. Int. J. Bipolar Disord., 3, 2015, 1, 10.1186/s40345-014-0017-6.
53. Pacchiarotti, I., Bond, D.J., Baldessarini, R.J., Nolen, W.A., Grunze, H., Licht, R.W., Post, R.M., Berk, M., Goodwin, G.M., Sachs, G.S., Tondo, L., Findling, R.L., Youngstrom, E.A., Tohen, M., Undurraga, J., González-Pinto, A., Goldberg, J.F., Yildiz, A., Altshuler, L.L., Calabrese, J.R., Mitchell, P.B., Thase, M.E., Koukopoulos, A., Colom, F., Frye, M.A., Malhi, G.S., Fountoulakis, K.N., Vázquez, G., Perlis, R.H., Ketter, T.A., Cassidy, F., Akiskal, H., Azorin, J.-M., Valentí M., Mazzei, D.H., Lafer, B., Kato, T., Mazzarini, L., Martínez-Aran, A., Parker, G., Souery, D., Ozerdem, A., McElroy, S.L., Girardi, P., Bauer, M., Yatham, L.N., Zarate, C.A., Nierenberg, A.A., Birmaher, B., Kanba, S., El-Mallakh, R.S., Serretti, A., Rihmer, Z., Young, A.H., Kotzalidis, G.D., MacQueen, G.M., Bowden, C.L., Ghaemi, S.N., Lopez-Jaramillo, C., Rybakowski, J., Ha, K., Perugi, G., Kasper, S., Amsterdam, J.D., Hirschfeld, R.M., Kapczinski, F., Vieta, E., The International Society for Bipolar Disorders (ISBD) task force report on antidepressant use in bipolar disorders. Am. J. Psychiatry 170 (2013), 1249–1262, 10.1176/appi.ajp.2013.13020185.
54. Park, S.W., Lee, J.G., Seo, M.K., Cho, H.Y., Lee, C.H., Lee, J.H., Lee, B.J., Baek, J.H., Seol, W., Kim, Y.H., Effects of mood-stabilizing drugs on dendritic outgrowth and synaptic protein levels in primary hippocampal neurons. Bipolar Disord. 17 (2015), 278–290, 10.1111/bdi.12262.
55. Peters, A.T., West, A.E., Eisner, L., Baek, J., Deckersbach, T., The burden of repeated mood episodes in bipolar i disorder: results from the national epidemiological survey on alcohol and related conditions. J. Nerv. Ment. Dis. 204 (2016), 87–94, 10.1097/NMD.0000000000000425.
56. Popovic, D., Reinares, M., Amann, B., Salamero, M., Vieta, E., Number needed to treat analyses of drugs used for maintenance treatment of bipolar disorder. Psychopharmacology (Berl.) 213 (2011), 657–667, 10.1007/s00213-010-2056-8.
57. Popovic, D., Reinares, M., Goikolea, J.M., Bonnin, C.M., Gonzalez-Pinto, A., Vieta, E., Polarity index of pharmacological agents used for maintenance treatment of bipolar disorder. Eur. Neuropsychopharmacol. 22 (2012), 339–346, 10.1016/j.euroneuro.2011.09.008 J. Eur. Coll. Neuropsychopharmacol.
58. Ricken, R., Adli, M., Lange, C., Krusche, E., Stamm, T.J., Gaus, S., Koehler, S., Nase, S., Bschor, T., Richter, C., Steinacher, B., Heinz, A., Rapp, M.A., Borgwardt, S., Hellweg, R., Lang, U.E., Brain-derived neurotrophic factor serum concentrations in acute depressive patients increase during lithium augmentation of antidepressants. J. Clin. Psychopharmacol. 33 (2013), 806–809, 10.1097/JCP.0b013e3182a412b8.
59. Severus, E., Taylor, M.J., Sauer, C., Pfennig, A., Ritter, P., Bauer, M., Geddes, J.R., Lithium for prevention of mood episodes in bipolar disorders: systematic review and meta-analysis. Int. J. Bipolar Disord., 2, 2014, 15, 10.1186/s40345-014-0015-8.
60. Soares-Weiser, K., Bravo Vergel, Y., Beynon, S., Dunn, G., Barbieri, M., Duffy, S., Geddes, J., Gilbody, S., Palmer, S., Woolacott, N., A systematic review and economic model of the clinical effectiveness and cost-effectiveness of interventions for preventing relapse in people with bipolar disorder. Health Technol. Assess. Winch. Engl. 11 (2007), iii–iiv ix–206.
61. Soeiro-de-Souza, M.G., Dias, V.V., Figueira, M.L., Forlenza, O.V., Gattaz, W.F., Zarate, C.A., Machado-Vieira, R., Translating neurotrophic and cellular plasticity: from pathophysiology to improved therapeutics for bipolar disorder. Acta Psychiatr. Scand. 126 (2012), 332–341, 10.1111/j.1600-0447.2012.01889.x.
62. Subramanian, K., Kattimani, S., Sarkar, S., Rajkumar, R.P., Current adherence attitudes can reflect the course and outcome of bipolar disorder-type I. Asian J. Psychiatry, 20, 2016, 11, 10.1016/j.ajp.2016.01.007.
63. Sylvia, L.G., Reilly-Harrington, N.A., Leon, A.C., Kansky, C.I., Calabrese, J.R., Bowden, C.L., Ketter, T.A., Friedman, E.S., Iosifescu, D.V., Thase, M.E., Ostacher, M.J., Keyes, M., Rabideau, D., Nierenberg, A.A., Medication adherence in a comparative effectiveness trial for bipolar disorder. Acta Psychiatr. Scand. 129 (2014), 359–365, 10.1111/acps.12202.
64. Tarr, G.P., Glue, P., Herbison, P., Comparative efficacy and acceptability of mood stabilizer and second generation antipsychotic monotherapy for acute mania–a systematic review and meta-analysis. J. Affect. Disord. 134 (2011), 14–19, 10.1016/j.jad.2010.11.009.
65. Teixeira, A.L., de Sousa, R.T., de Souza, R.T., Zanetti, M.V., Brunoni, A.R., Busatto, G.F., Zarate, C.A., Gattaz, W.F., Machado-Vieira, R., Increased plasma levels of soluble TNF receptors 1 and 2 in bipolar depression and impact of lithium treatment. Hum. Psychopharmacol. 30 (2015), 52–56, 10.1002/hup.2450.
66. Tunca, Z., Ozerdem, A., Ceylan, D., Yalçın, Y., Can, G., Resmi, H., Akan, P., Ergör, G., Aydemir, O., Cengisiz, C., Kerim, D., Alterations in BDNF (brain derived neurotrophic factor) and GDNF (glial cell line-derived neurotrophic factor) serum levels in bipolar disorder: The role of lithium. J. Affect. Disord. 166 (2014), 193–200, 10.1016/j.jad.2014.05.012.
67. van der Loos, M.L.M., Mulder, P., Hartong, E.G.T.M., Blom, M.B.J., Vergouwen, A.C., van Noorden, M.S., Timmermans, M.A., Vieta, E., Nolen, W.A., LamLit Study Group. Long-term outcome of bipolar depressed patients receiving lamotrigine as add-on to lithium with the possibility of the addition of paroxetine in nonresponders: a randomized, placebo-controlled trial with a novel design. Bipolar Disord. 13 (2011), 111–117, 10.1111/j.1399-5618.2011.00887.x.
68. Vieta, E., Berk, M., Schulze, T.G., Carvalho, A.F., Suppes, T., Calabrese, J.R., Gao, K., Miskowiak, K.W., Grande, I., Bipolar disorders. Nat. Rev. Dis. Primer, 4, 2018, 18008, 10.1038/nrdp.2018.8.
69. Vieta, E., Langosch, J.M., Figueira, M.L., Souery, D., Blasco-Colmenares, E., Medina, E., Moreno-Manzanaro, M., Gonzalez, M.A., Bellivier, F., Clinical management and burden of bipolar disorder: results from a multinational longitudinal study (WAVE-bd). Int. J. Neuropsychopharmacol. 16 (2013), 1719–1732, 10.1017/S1461145713000278.
70. Yasuda, S., Liang, M.-H., Marinova, Z., Yahyavi, A., Chuang, D.-M., The mood stabilizers lithium and valproate selectively activate the promoter IV of brain-derived neurotrophic factor in neurons. Mol. Psychiatry 14 (2009), 51–59, 10.1038/sj.mp.4002099.